V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 4.39 USD 3.29% Market Closed
Market Cap: 173.4m USD
Section:
 

Relative Value

The Relative Value of one VTGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 4.39 USD, VistaGen Therapeutics Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VTGN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

232
P/S
P/S
Price to Sales
232
vs History
23
vs Industry
13
Median 3Y
97.1
Median 5Y
120.4
Industry
7.9
Forward
220.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.8
Industry
23.7
Forward
-2.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2
Median 5Y
-3.1
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-3.1
Industry
23.8
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
39
vs Industry
59
Median 3Y
1.1
Median 5Y
2.1
Industry
3.3
More Details
120.6
EV/S
EV/S
Enterprise Value to Sales
120.6
vs History
33
vs Industry
54
Median 3Y
-8.1
Median 5Y
17.3
Industry
8.3
Forward
118.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
-0.1
Median 5Y
-0.4
Industry
6.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
-0.1
Median 5Y
-0.4
Industry
7
Forward
-1.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
-0.1
Median 5Y
-0.5
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
27
Median 3Y
-0.1
Median 5Y
-0.5
Industry
6.5
More Details
46.2
EV/IC
EV/IC
Enterprise Value to IC
46.2
vs History
23
vs Industry
50
Median 3Y
1.4
Median 5Y
6.8
Industry
5.7
More Details

Multiples Across Competitors

VTGN Competitors Multiples
VistaGen Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
VistaGen Therapeutics Inc
NASDAQ:VTGN
165.3m USD 232 -3.5 -1.7 -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
401.5B USD 6.7 171 16.5 23.5
US
Amgen Inc
NASDAQ:AMGN
173.9B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD 9.8 31.2 22.8 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD 16.2 1 192 156.5 189.8
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.9 58.4 60
P/E Multiple
Earnings Growth PEG
US
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Average P/E: 188.5
Negative Multiple: -3.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 192
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Average EV/EBITDA: 39.3
Negative Multiple: -1.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.4
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Average EV/EBIT: 45.3
Negative Multiple: -1.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
189.8
N/A N/A
NL
argenx SE
XBRU:ARGX
60
N/A N/A

See Also

Summary
VTGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
VTGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VTGN stock valuation using valuation multiples.
Wall Street Estimates
VTGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VTGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.